Ovarian cancer: identifying and managing familial and genetic risk

You can now review and comment on this draft guideline.

The consultation closes on Friday 27 October 2023 at 5pm

How to comment

1. Register your organisation or comment as an individual

If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder.

Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your comments to them.

We can accept comments from individuals. These will be considered, but you won’t get a formal response and they won’t be posted on the NICE website. Wherever possible we encourage you to submit your comments through a registered stakeholder organisation.

2. Read the consultation documents

Documents to comment on:

• Draft guideline

Evidence reviews

• Evidence review A – Information and support
• Evidence review B – Support interventions
• Evidence review C – Configuration of services
• Evidence review D – Optimal methods of assessing the probability of having a pathogenic variant
• Evidence review E – Optimal methods of assessing the absolute risk
• Evidence review F – Carrier probability – any person
• Evidence review G – Carrier probability - family history of a syndrome
• Evidence review H – Populations with high prevalence
• Evidence review I – Carrier probability - women with ovarian cancer
• Evidence review J – Which genes to include in test panel
• Evidence review K – Benefits and risks of surveillance
• Evidence review L – Methods of surveillance
• Evidence review M – Preventive medicines
• Evidence review N – Risk-reducing surgery
• Evidence review O – Pathology protocol
• Evidence review P – Hormone replacement therapy after risk-reducing surgery
• Economic model

Supporting documentation

• Methods
• Economic literature
• Developer team and expert witness list
• Equality impact assessment 

If you want to review the economic model, please see 5. Economic model below and fill in the confidentiality form

Other information about the consultation

• Committee membership list

Developing NICE guidelines: how to get involved

• Final scope – for information

3. Add your comments

• You must use this comments form
• You must declare any links with, or funding from, the tobacco industry

If you share similar views with another organisation, send a joint response.

Make sure you consider:

• The areas that will have the biggest impact on practice and be challenging to implement
• How to help users overcome challenges

Developing NICE guidelines: how to get involved suggests some other areas to comment on.

4. Email the form to us

Email: foc@nice.org.uk

Deadline: 5pm on Friday 27 October 2023

5. Economic model

The developer has produced an economic model to support the guideline on ovarian cancer: identifying and managing familial and genetic risk.  To receive an executable version of this model, please submit a request to foc@nice.org.uk with a signed copy of the confidentiality acknowledgement and undertaking form.

We will then send you a link to an executable version of the economic model by email. The deadline for returning your comments is the same as for the guideline consultation: 5pm on Friday 27 October 2023.